Harvard Bioscience Inc (HBIO)
LABORATORY ANALYTICAL INSTRUMENTS
Harvard Bioscience Inc (HBIO) is listed on Nasdaq, where it has traded since December 7, 2000.
- Listed On
- Nasdaq
- Listed Since
- December 7, 2000
- Employees
- 339
- Market Cap
- $44M
About Harvard Bioscience Inc
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 35 institutions reported holding HBIO, with 1.7 million shares worth $10.3 million in aggregate. The largest reported holder was Weber Capital Management LLC /Adv, with 310,861 shares worth $1.9 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Weber Capital Management LLC /Adv | 310,861 | $2M | Reduced 2.87% |
| Vanguard | 198,576 | $1M | Added 3.28% |
| Meros Investment Management | 182,992 | $1M | Added 54.39% |
| Acadian Asset Management | 179,614 | $1M | Unchanged |
| Nano Cap New Millennium Growth Fund L P | 143,082 | $880K | Added 21.77% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is HBIO?
Harvard Bioscience Inc (HBIO) is listed on Nasdaq, where it has traded since December 7, 2000.
Who are the largest institutional holders of HBIO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of HBIO were Weber Capital Management LLC /Adv, Vanguard and Meros Investment Management.
How many institutions own HBIO?
35 institutions reported a position in HBIO for the quarter ended June 30, 2026, worth $10.3 million in total.
Did institutions buy or sell HBIO last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for HBIO.
Every reported institutional holder, plus insider and congressional trades in HBIO, on SentiSense.